

AbbVie Pipeline Update

October 2026



abbvie

AbbVie R&D Pipeline

Phase 1

- ABBV-279 (IL-13 + OX40L) AD
- ABBV-313 (IL-13/IL-31R) AD
- ABBV-319 (CD19 ADC) SLE, Sjogren's Disease
- ABBV-333 (TSLP) Asthma
- ABBV-519 (CD19) RA, SLE
- ABBV-547 (IL-23) PsO
- ABBV-619 (CD19 CAR-T) RA, SLE
- ABBV-722 (LPAR1i) IPF
- ABBV-884 (IL-23/TL1A) IBD
- ABBV-859 (IL-23Ri) PsO
- ABBV-1451 (IL-1 α /1 β) HS
- ABBV-2294 (LPAR1i + JAK1i) RA, SSC
- Zumilokibart (IL-13) Asthma
- ABBV-253 (c-Met ADC) Solid Tumors
- ABBV-324 (GPC3 ADC) HCC / SQ-NSCLC
- ABBV-706 (SEZ6 ADC) Neuroendocrine Tumors
- ABBV-711 (PARP7i) Solid Tumors
- ABBV-901 (FR α ADC) Ovarian Cancer
- ABBV-969 (PSMA/STEAP1 ADC) mCRPC
- Alveltamig* (DLL3/DLL3/CD3) SCLC
- Azirkitig (ABBV-514) (CCR8) Solid Tumors
- KST-6051* (KRASi) Solid Tumors
- Temab-A (c-Met ADC) Ovarian
- ABBV-438 (CD38 ADC) R/R MM
- ABBV-2001* (CD38/BCMA/CD3) R/R MM
- SIM0500* (GPC3/CD3/BCMA/CD3) R/R MM
- Surzetocla (ABBV-453) (BCL2i) R/R MM
- UB-VV111* (CD19 CAR-T) LBCL, CLL
- ABBV-1042 (M4 Agonist) Bipolar Mania
- ABBV-1758 (3pE-A β) Alzheimer's Disease
- ABBV-7828 (JAK1i) Neurological Disorders
- Emraclidine (M4 PAM) Psychosis
- ABBV-6628 (C5) Geographic Atrophy

Phase 2

- ABBV-142 (LPAR1) IPF
- ABBV-166 (IL-1 α /1 β + IL-23) PsA
- ABBV-466 (α 4 β 7 + IL-23) CD/UC
- ABBV-701 (TL1A) RA
- ABBV-848 (IRAK4i) RA
- ABBV-7066 (TL1A + IL-23) CD/UC
- ABBV-8736 (TREM1) CD
- ABBV-8736 (TREM1) RA
- ABBV-9832 (IL-1 α /1 β + CD40) RA
- Zumilokibart (IL-13) AD
- ABBV-706 (SEZ6 ADC) 1L SCLC
- ABBV-1480* (PD-1/VEGF) + Temab-A (c-Met ADC) 1L NSCLC
- ABBV-1480* (PD-1/VEGF) + Temab-A (c-Met ADC) 1L/2L CRC
- Elahere (FR α ADC) Ovarian Cancer (FLORENZA)
- IMG-N-151 (FR α ADC) Gynecologic Cancers
- Temab-A (c-Met ADC) CRC
- Temab-A (c-Met ADC) GEA
- Temab-A (c-Met ADC) HNSCC
- Temab-A (c-Met ADC) Met-Amplified Tumors
- Temab-A (c-Met ADC) NSCLC
- Temab-A (c-Met ADC) PDAC
- Epkinly* (CD20/CD3) B-Cell NHL
- Epkinly* (CD20/CD3) R/R CLL and Richter's Syndrome
- Etentamig (BCMA/CD3) 1L MM
- Decnupaz (CD123 ADC) AML
- ABBV-932* (D2/D3 Agonist) Bipolar Depression
- ABBV-932* (D2/D3 Agonist) GAD
- ABBV-1354 (KOR Antagonist) Bipolar Depression
- ABBV-1354 (KOR Antagonist) MDD
- ABBV-2002 (PAR-2) Migraine Prevention
- Bretisiloin (5-HT2AR Agonist) MDD
- Emraclidine (M4 PAM) Schizophrenia
- GemibotA Essential Tremor
- GemibotA Ventral Hernia Repair
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucoma
- ABBV-295 (Amylin) Obesity

Registrational / Phase 3

- Lutikizumab (IL-1 α /1 β) HS
- Rinvoq (JAK1i) HS
- Rinvoq (JAK1i) SLE
- ABBV-706 (SEZ6 ADC) R/R SCLC
- ABBV-1480* (PD-1/VEGF) + Chemotherapy 1L NSCLC
- Elahere (FR α ADC) + Bevacizumab PSOC (GLORIOSA)
- Temab-A (c-Met ADC) + Bevacizumab 3L+ CRC
- Epkinly* (CD20/CD3) + Lenalidomide R/R DLBCL
- Epkinly* (CD20/CD3) + R-CHOP 1L DLBCL
- Epkinly* (CD20/CD3) + Rituximab/Lenalidomide 1L FL
- Etentamig (BCMA/CD3) + Pomalidomide 2L+ MM
- Etentamig (BCMA/CD3) 1L AL Amyloidosis
- Qulipta (CGRP) Menstrual Migraine Prevention
- Ubrelyv (CGRP) Menstrual Migraine Prevention
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery
- Armour Thyroid (T3/T4) Hypothyroidism

Submitted

- Rinvoq (JAK1i) Alopecia Areata (US)
- Rinvoq (JAK1i) Vitiligo (US)
- Etentamig (BCMA/CD3) 3L+ MM
- Boey Glabellar Lines (US)
- Reproxalap (RASAP)* Dry Eye Disease

- Immunology
- Oncology
- Neuroscience
- Aesthetics
- Eye Care
- Targeted Investment

As of October 30, 2026

Excludes devices in development

*AbbVie Partnered assets

New Clinical Programs: ABBV-884 Ph1 IBD, ABBV-253 Ph1 Solid Tumors, ABBV-7828 Ph1 Neurological Disorders, ABBV-701 Ph2 RA, ABBV-848 Ph2 RA, ABBV-8736 Ph2 RA, ABBV-1480 + Temab-A Ph2 1L NSCLC, ABBV-1480 + Temab-A Ph2 1L/2L CRC, Temab-A Ph2 HNSCC, Etentamig Ph2 1L MM, ABBV-295 Ph2 Obesity, ABBV-1480 + Chemotherapy Ph3 1L NSCLC, Etentamig/Pom Ph3 2L+ MM, Etentamig Ph3 1L AL Amyloidosis

Discontinued Clinical Programs: ABBV-243 Ph1 IBD

AbbVie - Anticipated Key Pipeline Events

	2026	2027
Regulatory Approvals	<p>Rinvoq Vitiligo*</p> <p>Skyrizi Crohn's Disease Subcutaneous Induction ✓</p> <p>Epkinly + Rituximab/Lenalidomide 2L FL (INTL) ✓</p> <p>Decnupaz BPDCN ✓</p> <p>Qulipta Migraine Acute Treatment (INTL) ✓</p> <p>Juvmo Parkinson's Disease ✓</p>	<p>Rinvoq Alopecia Areata*</p> <p>Epkinly + R-CHOP 1L DLBCL</p> <p>Etentamig Monotherapy 3L MM</p> <p>Qulipta Menstrual Migraine Prevention (EU)</p> <p>Ubrely Menstrual Migraine Prevention (US)</p> <p>Boey (TrenibotE) Glabellar Lines*</p>
Regulatory Submissions	<p>Rinvoq Vitiligo ✓</p> <p>Rinvoq Alopecia Areata ✓</p> <p>Skyrizi Crohn's Disease Subcutaneous Induction ✓</p> <p>Etentamig Monotherapy 3L MM ✓</p> <p>Qulipta Menstrual Migraine Prevention (EU)</p>	<p>Lutikizumab Hidradenitis Suppurativa</p> <p>Rinvoq Hidradenitis Suppurativa</p> <p>Rinvoq Systemic Lupus Erythematosus</p> <p>Elahere + Bevacizumab 2L PSOC Maintenance</p> <p>Epkinly + R-CHOP 1L DLBCL</p> <p>Epkinly + Lenalidomide 2L DLBCL Transplant Ineligible</p> <p>Ubrely Menstrual Migraine Prevention (US)</p> <p>ABBV-RGX-314 wAMD Subretinal Delivery</p>
Ph3/Registrational Data Readouts	<p>Lutikizumab Ph3 Hidradenitis Suppurativa ✓</p> <p>Rinvoq Ph3 Hidradenitis Suppurativa</p> <p>Skyrizi Ph3 Crohn's Disease Subcutaneous Induction ✓</p> <p>Epkinly + R-CHOP Ph3 1L DLBCL ✓</p> <p>Epkinly + Lenalidomide Ph3 2L DLBCL Transplant Ineligible ✓</p> <p>Etentamig Monotherapy Ph3 3L MM ✓</p> <p>Qulipta Ph3 Menstrual Migraine Prevention ✓</p> <p>Ubrely Ph3 Menstrual Migraine Prevention</p> <p>ABBV-RGX-314 Ph3 wAMD Subretinal Delivery</p>	<p>Rinvoq Ph3 Systemic Lupus Erythematosus</p> <p>Elahere + Bevacizumab Ph3 2L PSOC Maintenance</p> <p>Temab-A + Bevacizumab Ph3 3L+ CRC</p>
Early-Stage Data Readouts	<p>ABBV-466 (ABBV-382 + Skyrizi) Ph2 CD ✓</p> <p>ABBV-9832 (Lutikizumab + Ravagalinab) Ph2 RA</p> <p>ABBV-969 Ph1 mCRPC ✓</p> <p>ABBV-2001 Ph1 MM</p> <p>Etentamig Ph1 1L & 2L MM Combinations ✓</p> <p>IMGN-151 Ph2 PROC Monotherapy</p> <p>ABBV-932 Ph2 Bipolar Depression ✓</p> <p>Bretisiloin Ph2 MDD</p> <p>Emraclidine Ph2 Schizophrenia ✓</p> <p>Emraclidine Ph1 Psychosis ✓</p> <p>ABBV-295 Ph1 Obesity ✓</p> <p>ABBV-166 (Lutikizumab + Skyrizi) Ph2 CD ✓</p> <p>Livmoniplimab Ph2 1L NSCLC ✓</p>	<p>ABBV-319 Ph1 SLE/Sjogren's Disease</p> <p>ABBV-619 Ph1 RA/SLE</p> <p>ABBV-166 (Lutikizumab + Skyrizi) Ph2 PsA</p> <p>ABBV-514 Ph1 Solid Tumors</p> <p>Surzetoclax Ph1 MM</p> <p>Temab-A Ph2 comboTx 1L CRC</p> <p>Temab-A Ph2 comboTx 2L CRC</p> <p>Temab-A Ph2 comboTx 1L GEA</p> <p>Temab-A Ph2 comboTx 1L NSCLC</p> <p>Temab-A Ph2 comboTx 2L NSCLC EGFR-mutant</p> <p>ABBV-932 Ph2 Generalized Anxiety Disorder</p> <p>ABBV-1354 Ph2 MDD</p> <p>ABBV-2002 Ph2 Migraine Prevention</p> <p>ABBV-RGX-314 Ph2 wAMD Suprachoroidal Delivery</p>

As of October 30, 2026

*Rinvoq approved for alopecia areata and vitiligo in Europe; Boey approved for glabellar lines in Europe

AbbVie's Partnered Assets

- ABBV-932 developed in partnership with Gedeon Richter.
- ABBV-1480 (RC148) developed in partnership with RemeGen.
- ABBV-2001 developed in partnership with Ichnos Glenmark Innovation (IGI).
- ABBV-RGX-314 co-developed by REGENXBIO and AbbVie.
- Alveltamig developed by Suzhou Zelgen Biopharmaceuticals. AbbVie holds an exclusive option to develop and commercialize Alveltamig.
- KST-6051 developed by Kestrel Therapeutics. AbbVie holds an exclusive option to acquire Kestrel.
- Epkinly developed in partnership with Genmab.
- Reproxalap currently developed by Aldeyra. AbbVie holds an exclusive option to license, co-develop, and co-commercialize reproxalap.
- SIM0500 developed by Simcere Zaiming. AbbVie holds an exclusive option to develop and commercialize SIM0500.
- UB-VV111 developed by Umoja Biopharma. AbbVie holds an exclusive option to develop and commercialize UB-VV111.